RGNX Latest Press Releases

-- November 5, 2026 --

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- November 3, 2026 --

REGENXBIO to Participate in Stifel 2026 Healthcare Conference PRNewswire 7:05 AM

-- October 29, 2026 --

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- October 12, 2026 --

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 PRNewswire 7:05 AM

-- September 24, 2026 --

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting PRNewswire 7:18 PM

-- September 8, 2026 --

REGENXBIO to Participate in Upcoming Investor Conferences PRNewswire 7:05 AM

-- August 25, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX) Business Wire 12:53 PM

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PRNewswire 7:05 AM

-- August 24, 2026 --

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold Globe Newswire 2:18 PM

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II PRNewswire 7:06 AM

-- August 6, 2026 --

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- August 3, 2026 --

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- July 21, 2026 --

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm PRNewswire 7:29 PM

-- July 18, 2026 --

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting PRNewswire 2:55 PM

-- July 17, 2026 --

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants PRNewswire 7:00 AM

-- July 16, 2026 --

REGENXBIO Announces Proposed Public Offering of Common Stock PRNewswire 4:27 PM

-- July 13, 2026 --

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm Globe Newswire 3:32 PM

-- June 29, 2026 --

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone PRNewswire 7:05 AM

-- June 24, 2026 --

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 PRNewswire 7:05 AM

-- June 22, 2026 --

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II PRNewswire 7:30 AM

Market Data Delayed 15 Minutes